Immunome (IMNM) Net Income Growth (3y) (2022 - 2026)

Immunome (IMNM) Net Income Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Oculis Holding AG 66,380.63 Bn 66,380.34 Bn - 9.16%
2 Nanobiotix 1,910.39 Bn 1,910.33 Bn - -
3 Akari Therapeutics 959.56 Bn 959.56 Bn - -
4 BeOne Medicines 470.95 Bn 466.16 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 121.97 Bn 114.72 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 69.92 Bn 61.16 Bn 3.31 Bn -3.84%
7 Belite Bio 62.06 Bn 62.06 Bn - -
8 Argenx Se 55.76 Bn 50.58 Bn 1.41 Bn 79.26%
9 Alnylam Pharmaceuticals 37.50 Bn 34.49 Bn 959.66 Mn 47.10%
10 Immunome 2.61 Bn 2.02 Bn - -276.65%

Historic Data

Download Data
DateValue
Mar 31, 2026 -276.65%
Dec 31, 2025 -108.38%
Sep 30, 2025 -104.39%
Jun 30, 2025 -87.15%
Mar 31, 2025 -56.32%
Dec 31, 2024 -119.78%
Sep 30, 2024 -146.82%
Jun 30, 2024 -49.05%
Mar 31, 2024 -221.16%
Dec 31, 2023 -183.70%
Sep 30, 2023 2.94%
Jun 30, 2023 -80.55%
Mar 31, 2023 -19.61%
Dec 31, 2022 -40.51%
Sep 30, 2022 -63.37%